pharma · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Paroxysmal Nocturnal Haemoglobinuria (PNH) · AKTX
Akari Therapeutics
Akari Therapeutics Plc
Akari Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker AKTX. Primary therapeutic focus areas include Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Haemog
London, GB HQ
16 Employees
Public company Type
AKTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 16
- Programs
- 9
- Drugs
- 0
- Patents
- 0
rVA576
Phase 2 · small molecule · Keratoconjunctivitis, Atopic
rVA576 for Keratoconjunctivitis, Atopic is a Phase 2 program (small_molecule) at Akari Therapeutics Plc with 1 ClinicalTrials.gov record(s).
Internal code AK701
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Akari Therapeutics Plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Keratoconjunctivitis, Atopic
- Status
- terminated
- Trials
- 1